IP Library Granted Patent US 11,098,291
Granted Patent B2
US 11,098,291 · App. 16/707,724 · Granted Aug 24, 2021

Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs

Inventors: Jovana Nazor (Milpitas, CA); Derek J. Smith (Singapore, SG); Michael A. Crowe (Singapore, SG); Shiwei Song (Singapore, SG); Steven J. Collier (Concord, MA)
Assignee: Codexis, Inc.
C12N9/1096C12P17/10C12Y206/01C12Y206/01018Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,098,291
App. No.
16/707,724
Granted
Aug 24, 2021
Kind
B2
Abstract

The present disclosure provides engineered transaminase polypeptides for the production of amines, polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to prepare compounds useful in the production of active pharmaceutical agents.

Claims (20)

1. An engineered polypeptide having transaminase activity, comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 134 and residues difference as compared to SEQ ID NO: 2 at residue positions X14, X391 and X427.

2. The engineered polypeptide of claim 1 , further comprises one or more further residue differences as compared to SEQ ID NO:2 at residue positions selected from: X26, X31, X33, X57, X86, X88, X113, X148, X163, X168, X173, X203, X250, X284, X314, X315, X324, X346, X398, X400, X417, and X448.

3. The engineered polypeptide of claim 1 , wherein the residue difference at the residue position X14 is X14V.

4. The engineered polypeptide of claim 1 , wherein the amino acid sequence further comprises at least one or more residue differences selected from X26R, X31S/D, X86D, X163I/L/R/V, X315G, X398L/V/W, and X400G.

5. The engineered polypeptide of claim 1 , wherein the amino acid sequence further comprises a combination of residue differences selected from:

X163I/L/R/V,

X86D and X400G,

X57F/Y and X163I/L/R/V,

X57F/Y and X398L/V/W,

X163I/L/R/V, and X424V,

X31S, X57F/Y, X163I/L/R/V, X315G, X346L, and X398L/V/W,

X26R, X163L, and X400G,

X26R and X88L,

X57F, X163L, X168K, X314N, X315G, X346L, and X398V,

X163L, X173A, X400G, and X420N,

X26R, X163L, and X400G, and

X33T, X57F, and X163L.

6. The engineered polypeptide of claim 1 , wherein said polypeptide has at least 1.2 fold increased stability as compared to the polypeptide of SEQ ID NO:4.

7. The engineered polypeptide of claim 1 , wherein the amino acid sequence comprises SEQ ID NO: 134.

8. The engineered polypeptide of claim 1 , wherein said polypeptide is immobilized on a solid support.

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (6)
Continuation 15623698 · Jun 15, 2017
Continuation 15180355 · Jun 13, 2016
Division 14828839 · Aug 18, 2015
Division 14386082
Provisional Application 61614666 · Mar 23, 2012
Related Publication 20200123512A1 · Apr 23, 2020
Cited By (1)
US 12,668,824